4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Non-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine (NCRNAPAIN)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs (ncRNAs) regulate both immune and neuronal processes. Therefore, ncRNAPain proposes that ncRNAs are critically important master switches for chronic pain.ncRNAPain represents a multidisciplinary consortium of clinical partners, molecular and systems-level n ...
Voir le projet
12
Participants partenaires
TERMINÉ
Exgenome Molecular Enzymes (EXGENOMES)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2013,
... in the research industry today. The partner SME´s are all active players in this area from bioprospecting (Prokazyme), laboratory distribution (A&A Biotechnologies), LNA manufacture & diagnostics (Exiqon) to DNA vaccine production (Touchlight Genetics).Together with the highly competent RTD partners the consortium is well positioned to implement the project according to its goals. The successful ...
Voir le projet
8
Participants partenaires
TERMINÉ
MicroRNAs and Cancer: From Bench to Bedside (ONCOMIRS)
Date du début: 1 févr. 2008, Date de fin: 31 janv. 2013,
"Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that specific microRNAs (miRs) and molecules involved in their biogenesis contribute to tumorigenesis. The ONCOMIRS consortium proposes a natural succession of four experimental strategies. Fist, we will DISCOVER and unveil novel miRs and components of their biogenesis machinery and investigate lin ...
Voir le projet
8
Participants partenaires
TERMINÉ
Prostate cancer: profiling and evaluation of ncRNA (ProspeR)
Date du début: 1 févr. 2008, Date de fin: 31 juil. 2012,
Annually, over 200 000 new prostate cancer cases are diagnosed in Europe. This number is expected to further increase due to widespread use of prostate specific antigen (PSA) tests on asymptomatic men and an aging population. This leads to high rate of over-detection, where most cases will never experience cancer symptoms during their lifetime. Hence, our current lack of means to predict prostate ...
Voir le projet